- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
May2017
API 2017 (Panama | May 16-20)
Two posters highlighting the use of Tersan’s Real World Evidence (RWE) platform for large scale data mining of healthcare records are to be presented at API 2017 (Asociacion Panamericana de Infectologia) – XVIII Congresso Panamericano de Infectologia, Panama, 16-20 May 2017. The studies focus on retrospective analyses of risk factors for dengue mortality in hospitalized […]
May2017
Broadening the reach of Precision Medicine beyond DNA
Initial results of Onco KEM and the WINTHER trial were presented at TAT 2017: 15th International Congress on Targeted Anticancer Therapies, 6-8 Mar 2017, Paris, France. The study demonstrates that the innovative Onco KEM transcriptomic-based decision support system fills a gap left by traditional DNA based targeted therapy, enabling more patients to reach a larger […]
Nov2016
Tersan to present on Combination Therapy in Melanoma with Harvard Medical School (Paris | Nov 29 – Dec 2nd)
Dr Parmentier will present a poster “Combination Therapy in Melanoma: finding biomarkers of synergistic associations using Large Scale Drug Combination Screening and integrated Omics Data Analysis” at the Institut Pasteur International Network Scientific Symposium in Paris on November 30th. The poster showcases the results of a collaborative study between Tersan and the Massachusetts General […]
Nov2016
Tersan to showcase Real World Evidence platform at ASTMH 2016 (Atlanta, USA | Nov 13-17)
Dr David Morley, VP Computational Technology, will be co-presenting a poster at the 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH 2016) in Atlanta, USA. Poster 212 “Management of dengue hospitalizations in Brazil during and outside epidemic periods: Insights from Data Mining” is a joint presentation with Sanofi Pasteur and […]
Oct2016
Anavex and Tersan Pharmaceuticals Ltd Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
NEW YORK, NY – October 5, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced a collaboration with Tersan Pharmaceuticals Ltd […]
Sep2016
Tersan Pharmaceuticals Ltd (Paris, Boston) and ValiSeek (London) to collaborate on Phase II Non-small Cell Lung Cancer treatment
Tersan’s advanced data analytics, using its KEM® decision support platform, will help ValiSeek boost success outlook. Tersan® Pharma, a leading digital health Company focused on developing advanced personalized therapeutic decision support systems and a provider of decision support tools and services to accelerate drug development, announces today that it has won a significant contract of […]
Jul2016
Tersan Pharmaceuticals Ltd joins the Healthcare Data Institute
Tersan is pleased to announce that the company has joined the Healthcare Data Institute. The Healthcare Data Institute is the first international think tank dedicated to Big Data in the health sector. An Orange Healthcare initiative, the Healthcare Data Institute was launched in partnership with other companies representative of the Big Data health ecosystem: […]
Jul2016
Pharma Boardroom interview with Mohammad Afshar
Interview with Mohammad Afshar – CEO, Tersan Pharmaceuticals Ltd, France, 12 July 2016 Mohammad Afshar, CEO of Tersan Pharmaceuticals Ltd, shares his insights on the importance of decision support tools, big data’s impact on the healthcare industry, and the need to translate this data into the production of real products. He also discusses the challenges he faced […]
Jun2016
Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables
Tersan Pharmaceuticals Ltd and Laboratoires Pierre Fabre have recently published the results of a clinical data mining study using KEM to identify the best responder subgroups for Milnacipran in fibromyalgia. “Is the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome Variables”, Lilia Abtroun, PhD, Pierre Bunouf, PhD, Roger M Gendreau, MD, […]
Jun2016
WIN 2016 Symposium (Paris | June 27-28)
The WIN 2016 Symposium is the place to be to learn about the latest in cancer research by world class presenters. Come and meet the Tersan team of Dr Mohammad Afshar, Dr Guergova-Kuras, Dr Morley and Dr Vaucouleur.